Let's Talk About Risk: FDA Plans Meeting On Postmarket Risk Management
This article was originally published in The Gray Sheet
Executive Summary
FDA says it will hold an interactive workshop on April 21 to discuss the "clinical considerations of risk in the postmarket environment." The meeting will build on a process launched last fall when representatives from industry and FDA met to establish draft principles for managing unanticipated risks for marketed devices.